[1] C. Sun, H. Yang, Y. Yuan et al., "Controlling assembly of paired gold clusters within apoferritin nanoreactor for in vivo kidney targeting and biomedical imaging," J. Am. Chem. Soc. 133, 8617– 8624 (2011).
[2] X. J. Liang, C. Chen, Y. Zhao, L. Jia, P. C. Wang, "Biopharmaceutics and therapeutic potential of engineered nanomaterials," Curr. Drug. Metab. 9 (8), 697–709 (2008).
[3] A. E. Farah, "Glucagon and the circulation," Pharmacol. Rev. 35(3), 181–217 (1983).
[4] L. S. Weisberg, R. Zanger, "Minerals in dialysis therapy: An introduction," Semin. Dial. 23(6), 547– 548 (2010).
[5] J. P. Hayslett, "Functional adaptation to reduction in renal mass," Physiol. Rev. 59(1), 137–164 (1979).
[6] B. F. Miller, A. Leaf, A. R. Mamby, Z. Miller, "Validity of the endogenous creatinine clearance as a measure of glomerular filtration rate in the diseased human kidney," J. Clin. Invest. 31(3), 309– 313 (1952).
[7] H. S. Choi, W. Liu et al., "Design considerations for tumour-targeted nanoparticles," Nat. Nanotechnol. 5(1), 42–47 (2010).
[8] W. H. De Jong, W. I. Hagens, P. Krystek et al., "Particle size-dependent organ distribution of gold nanoparticles after intravenous administration," Biomaterials 29(12), 1912–1919 (2008).
[9] R. Kumar, I. Roy, T. Y. Ohulchanskky et al., "In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles," ACS Nano 4(2), 699–708 (2010).
[10] M. Li, K. T. Al-Jamal, K. Kostarelos et al., "Physiologically based pharmacokinetic modeling of nanoparticles," ACS Nano 4(11), 6303–6317 (2010).
[11] M. A. Rubin, M. P. Zerkowski, R. L. Camp et al., "Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): A novel paradigm for automated and continuous biomarker measurements," Am. J. Pathol. 164, 831–840 (2004).
[12] A. Psyrri, Z. Yu, P. M. Weinberger et al., "Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis," Clin. Cancer Res. 11, 5856–5862 (2005).
[13] R. M. Levenson, A. Fornari, M. Loda, "Multispectral imaging and pathology: Seeing and doing more," Expert Opin. Med. Diagn. 2, 1067–1081 (2008).
[14] E. Dimmock, D. Franks, A. M. Glauert, "The location of blood group antigen A on cultured rabbit kidney cells as revealed by ferritin-labelled antibody," J. Cell Sci. 10(2), 525–533 (1972).
[15] F. Grinnell, D. C. Hays, "Measurement of anionic sites on the surfaces of baby hamster kidney cells using radiolabeled polycationic ferritin," Anal. Biochem. 97(2), 400–402 (1979).
[16] J. Y. Li, N. Paragas, R. M. Ned et al., "Scara5 is a ferritin receptor mediating non-transferrin iron delivery," J. Dev. Cell 16(1), 35–46 (2009).
